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PLASMIC Score
FSGS HTN MAHA
Our patient is a 19 year old male with no past medical history who presented to the
emergency department with nausea, vomiting, subjective fever, and fatigue for roughly
two weeks. He stated that he had been sleeping most of the day, had been unable to
keep anything down, and was unable to attend work. He described feeling feverish at
some point, but did not take his temperature.
Social history was positive for social marijuana use (last use was >1 week prior), social
alcohol use. He works part time in the warehouse of a grocery store.
Family history was remarkable for early death in his mother, in her mid-30’s. Cause of
death was unknown, possibly related to an overdose. The patient has been under the
care of his aunt ever since.
He had never had surgery, no allergies, and took no daily medications prior to arrival.
Vitals: BP 229/142, HR 92, RR 18, 100% RA, T 98.9oF
The patient was markedly hypertensive on presentation. Physical exam was significant
for scleral icterus and the patient was slow to respond to questions, with an otherwise
intact neurological exam. Initial blood work revealed renal failure, anemia, and
thrombocytopenia. Examination of the peripheral smear demonstrated marked
schistocytosis.
The patient was started on nicardipine infusion for hypertensive emergency and was
empirically treated for TTP with emergent plasma exchange (PEX). He underwent 3
sessions of PEX, until platelets were above 100K. He was started on oral therapy with
hydralazine, metoprolol, and nicardipine and was able to be weaned off of the
nicardipine drip after 4 days. His creatinine remained 6.5+ throughout his admission. He
underwent renal biopsy that demonstrated changes consistent with focal segmental
glomerulosclerosis. ADAMTS13 resulted two weeks after his presentation and was within
normal limits.
The patient was discharged home on: hydralazine, metoprolol tartrate, nifedipine and
calcium acetate. He has been following with nephrology as an outpatient, though has
missed his last several appointments.
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This patient’s presentation was concerning for TTP due to severe
thrombocytopenia and MAHA. Given the prolonged turnaround time for the
ADAMTS13 assay, he was empirically treated for TTP with PEX. However, in
hindsight we believe this patient developed FSGS with subsequent renal
hypertension that went undiagnosed and untreated for an unknown period of
time, leading to his presentation of MAHA secondary to hypertensive crisis.
It is difficult to discern TTP from other causes of MAHA. One helpful tool is
called the PLASMIC score which estimates the likelihood of severe
ADAMTS13 deficiency in adults with possible TTP.
The average turnaround time for ADAMTS13 is prolonged. Our patient’s assay
did not result for >2 weeks. A study at Brigham and Women’s Hospital in
2016 with rapid in-house assay reduced number of plasma exchanges for
suspected TTP by more than half without an increase in mortality. A second
study in 2017 demonstrated that a rapid assay for ADAMTS13 was
associated with reduced mortality for patient’s diagnosed with TTP.
An article published in 2015 analyzed 19 cases of hypertension induced
MAHA via literature review. About 1/3 of the patients underwent PLEX while
awaiting ADAMTS13 results. At the time of presentation, all had significant
hypertension with MAPs ranging from 123-190 and prominent renal
dysfunction, with milder thrombocytopenia.
As the mortality rate of Thrombotic Thrombocytopenic Purpura approaches
90% when not treated with plasma exchange, it is understandable that
providers err on the side of caution when choosing whom to treat. Until there
is a readily available rapid in-house assay for ADAMTS13, the decision to
initiate empiric treatment for TTP will rely on clinical judgment with perhaps
some assistance from the PLASMIC scoring system.
Introduction
It is established that Focal Segmental Glomerulosclerosis (FSGS) can lead to
difficult to control hypertension. It has also been shown that malignant
hypertension can cause microangiopathic hemolytic anemia (MAHA).
Distinguishing MAHA due to malignant hypertension from other causes of MAHA
such as Thrombotic Thrombocytopenic Purpura (TTP) or Hemolytic Uremic
Syndrome (HUS) can be difficult. We present an interesting case of a young patient
who we believe developed undiagnosed FSGS that led to hypertensive crisis, acute
renal failure, and MAHA.
Case Description
LDH 1,093
AST 48
ALT 25
T bili 2.1
D bili 0.4
Haptoglobin <30.0
Discussion
1 point for each:
 Platelet count <30,000/microL
 One or more of the following: 
reticulocyte count >2.5%, haptoglobin 
undetectable, or indirect bilirubin >2.0 mg/dL
 No active cancer in the preceding year
Pictured above: our patient’s peripheral blood smear. Two examples of schistocytes
are highlighted with blue arrows. Up to 12/hpf were noted in pathology report.
Official pathology report: Microangiopathic hemolytic anemia is suspected in view of
marked schistocytosis, thrombocytopenia and anemia with polychromasia. Among
other causes for presence of schistocytes, hypertensive crisis or mechanical
hemolysis due to artificial heart valves is to be ruled out.
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PLASMIC score 
(points)
Risk of Severe 
ADAMTS13 deficiency
0-4 Low
5 Intermediate
6-7 high
 No history of solid organ or hematopoietic stem 
cell transplant
 MCV <90 fl
 INR <1.5
 Creatinine <2.0mg/dL
A high PLASMIC score (6-7) has a 
sensitivity ~91%. A low (0-4) score has 
a specificity of 99%.  The PLASMIC 
score was applied to 108 patients with 
suspected TMA. The system had a 
positive predictive value of 72%, and a 
negative predictive value of 99%.
Our patient’s PLASMIC score was 5.
Microangiopathic Hemolytic Anemia (MAHA) - descriptive term for non-immune
hemolysis, red blood cell fragmentation that takes place inside the vasculature.
Thrombotic Microangiopathy (TMA) - microvascular thrombosis caused by
abnormalities in the vessel walls of capillaries and arterioles. Diagnosis made by
tissue biopsy.
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